Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.33 |
| ▸ | NPC1 | O15118 | 7/20 | 0.33 |
| ▸ | RAB9A | P51151 | 7/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134201 | 0.81 | GSTO1 (0.36) | CYP3A4LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL13134203 | 0.80 | BAZ1A (0.37) | CYP3A4LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4517468 | 0.79 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL4957408 | 0.78 | SMN1; SMN2 (0.36) | CYP3A4LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5495466 | 0.78 | CYP3A4 (0.49) | CYP3A4LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL13134383 | 0.77 | CYP3A4 (0.31) | CYP3A4LMNASMN1; SMN2 | |
| SCHEMBL788917 | 0.76 | PKN1 (0.33) | IKBKBMAPK1 | |
| SCHEMBL9654498 | 0.75 | EGFR (0.40) | CYP3A4 | |
| SCHEMBL31268919 | 0.72 | HSD17B10 (0.40) | CYP3A4LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL12503869 | 0.72 | HSD17B10 (0.40) | CYP3A4LMNAALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7303739-B2 | Prodrugs for liver specific drug delivery | METABASIS THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-05-12 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | PYGL, PHOSPHO1, OAT | CYP3A4 94/4885LMNA 3367/4885SMN1; SMN2 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.